MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ribavirin

CAS No. : 36791-04-5

MCE 站：Ribavirin

产品活性：Ribavirin (ICN-1229) 是广谱的抗病毒药，可抑制HCV，HIVl，RSV等病毒。

研究领域：Anti-infection

作用靶点：HCV  |  RSV  |  Antibiotic

In Vitro: Treatmentof LPS-stimulated microglia with 5, 10 and 20 μM Ribavirin (ICN-1229) induces reduction of NO₂ levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia. Ribavirin (ICN-1229) is active against DENV, with an EC₅₀ of 3 μM in A549 cells, and combination of CM-10-18 with Ribavirin (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication.

In Vivo: ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin (ICN-1229) (p<0.01). JAT, interferon or ribavirin alone with CCl₄, livers appear to exhibit some liver protection against CCl₄ as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin (ICN-1229), and JAT, the expression level of p53 is markedly reduced. Ribavirin (ICN-1229) capsules (400 mg of ribavirin)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin (ICN-1229) has strong antiviral activity only when ribavirin is combined with either IFN-α or Peg-IFN-α. Ribavirin (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Nucleotide Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Anti-Hepatitis C Virus Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rapamycin  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Cycloheximide  |  Chloroquine  |  Staurosporine  |  Dexamethasone  |  Doxycycline (hyclate)  |  Actinomycin D  |  Cyclosporin A  |  G-418 disulfate  |  5-Azacytidine  |  Etoposide  |  Mitomycin C  |  Nigericin sodium salt  |  Brefeldin A  |  Wortmannin  |  Resveratrol  |  Resiquimod  |  Tunicamycin  |  Bleomycin sulfate  |  Hygromycin B  |  Tacrolimus  |  Ionomycin  |  Vancomycin hydrochloride  |  Streptozocin  |  Tanespimycin  |  Oligomycin A

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。